These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 30771580)

  • 1. Trial of intrathecal rituximab in progressive multiple sclerosis patients with evidence of leptomeningeal contrast enhancement.
    Bhargava P; Wicken C; Smith MD; Strowd RE; Cortese I; Reich DS; Calabresi PA; Mowry EM
    Mult Scler Relat Disord; 2019 May; 30():136-140. PubMed ID: 30771580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of MRI leptomeningeal enhancement with disability worsening in progressive multiple sclerosis: A clinical and post-mortem study.
    Vercellino M; Costantini G; Cogoni M; Lequio L; Sciortino P; De Negri F; Marasciulo S; Valentini C; Bosa C; Garelli P; Rolando A; Calvo A; Morana G; Cavalla P
    Mult Scler; 2023 Nov; 29(13):1526-1539. PubMed ID: 37740714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of intrathecal rituximab on biomarkers in multiple sclerosis.
    Topping J; Dobson R; Lapin S; Maslyanskiy A; Kropshofer H; Leppert D; Giovannoni G; Evdoshenko E
    Mult Scler Relat Disord; 2016 Mar; 6():49-53. PubMed ID: 27063622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Highly Sensitive 3-Tesla Real Inversion Recovery MRI Detects Leptomeningeal Contrast Enhancement in Chronic Active Multiple Sclerosis.
    Okar SV; Dieckhaus H; Beck ES; Gaitán MI; Norato G; Pham DL; Absinta M; Cortese IC; Fletcher A; Jacobson S; Nair G; Reich DS
    Invest Radiol; 2024 Mar; 59(3):243-251. PubMed ID: 37493285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 7T MRI cerebral leptomeningeal enhancement is common in relapsing-remitting multiple sclerosis and is associated with cortical and thalamic lesions.
    Zurawski J; Tauhid S; Chu R; Khalid F; Healy BC; Weiner HL; Bakshi R
    Mult Scler; 2020 Feb; 26(2):177-187. PubMed ID: 31714181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leptomeningeal Enhancement on 3D-FLAIR MRI in Multiple Sclerosis: Systematic Observations in Clinical Practice.
    Titelbaum DS; Engisch R; Schwartz ED; Napoli SQ; Sloane JA; Samaan S; Katz JD; Lathi ES
    J Neuroimaging; 2020 Nov; 30(6):917-929. PubMed ID: 32830899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Focal cortical atrophy following transient meningeal enhancement in a progressive multiple sclerosis.
    Bonnan M; Money P; Desblache P; Marasescu R; Puvilland LM; Demasles S; Dahan C; Krim E; Tucholka A; Doyle S; Barroso B
    Neurol Sci; 2021 May; 42(5):1959-1961. PubMed ID: 32995987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No association between cortical lesions and leptomeningeal enhancement on 7-Tesla MRI in multiple sclerosis.
    Ighani M; Jonas S; Izbudak I; Choi S; Lema-Dopico A; Hua J; O'Connor EE; Harrison DM
    Mult Scler; 2020 Feb; 26(2):165-176. PubMed ID: 31573837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natalizumab in progressive MS: results of an open-label, phase 2A, proof-of-concept trial.
    Romme Christensen J; Ratzer R; Börnsen L; Lyksborg M; Garde E; Dyrby TB; Siebner HR; Sorensen PS; Sellebjerg F
    Neurology; 2014 Apr; 82(17):1499-507. PubMed ID: 24682973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intrathecal treatment trial of rituximab in progressive MS: An open-label phase 1b study.
    Bergman J; Burman J; Gilthorpe JD; Zetterberg H; Jiltsova E; Bergenheim T; Svenningsson A
    Neurology; 2018 Nov; 91(20):e1893-e1901. PubMed ID: 30305449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy.
    Salzer J; Svenningsson R; Alping P; Novakova L; Björck A; Fink K; Islam-Jakobsson P; Malmeström C; Axelsson M; Vågberg M; Sundström P; Lycke J; Piehl F; Svenningsson A
    Neurology; 2016 Nov; 87(20):2074-2081. PubMed ID: 27760868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leptomeningeal gadolinium enhancement across the spectrum of chronic neuroinflammatory diseases.
    Absinta M; Cortese IC; Vuolo L; Nair G; de Alwis MP; Ohayon J; Meani A; Martinelli V; Scotti R; Falini A; Smith BR; Nath A; Jacobson S; Filippi M; Reich DS
    Neurology; 2017 Apr; 88(15):1439-1444. PubMed ID: 28283598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pilot trial of ocrelizumab for modulation of meningeal enhancement in multiple sclerosis.
    Dahal S; Allette YM; Naunton K; Harrison DM
    Mult Scler Relat Disord; 2024 Jan; 81():105344. PubMed ID: 38035495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meningeal contrast enhancement in multiple sclerosis: Assessment of field strength, acquisition delay, and clinical relevance.
    Harrison DM; Allette YM; Zeng Y; Cohen A; Dahal S; Choi S; Zhuo J; Hua J
    PLoS One; 2024; 19(5):e0300298. PubMed ID: 38809920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Location matters: highly divergent protein levels in samples from different CNS compartments in a clinical trial of rituximab for progressive MS.
    Bergman J; Svenningsson A; Liv P; Bergenheim T; Burman J
    Fluids Barriers CNS; 2020 Jul; 17(1):49. PubMed ID: 32727487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab for secondary progressive multiple sclerosis: a case series.
    Rommer PS; Patejdl R; Winkelmann A; Benecke R; Zettl UK
    CNS Drugs; 2011 Jul; 25(7):607-13. PubMed ID: 21699272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leptomeningeal enhancement under different MS immunotherapies: A monocentric retrospective cohort study of 214 patients.
    Friedli C; Wagner F; Hammer HN; Kamber N; Wiest R; Diem L; Chan A; Salmen A; Hoepner R
    Mult Scler; 2023 Jan; 29(1):63-73. PubMed ID: 36113094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leptomeningeal enhancement in multiple sclerosis and other neurological diseases: A systematic review and Meta-Analysis.
    Ineichen BV; Tsagkas C; Absinta M; Reich DS
    Neuroimage Clin; 2022; 33():102939. PubMed ID: 35026625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peripheral B cell depletion and central proinflammatory cytokine reduction following repeated intrathecal administration of rituximab in progressive Multiple Sclerosis.
    Studer V; Rossi S; Motta C; Buttari F; Centonze D
    J Neuroimmunol; 2014 Nov; 276(1-2):229-31. PubMed ID: 25175066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leptomeningeal Contrast Enhancement Is Related to Focal Cortical Thinning in Relapsing-Remitting Multiple Sclerosis: A Cross-Sectional MRI Study.
    Bergsland N; Ramasamy D; Tavazzi E; Hojnacki D; Weinstock-Guttman B; Zivadinov R
    AJNR Am J Neuroradiol; 2019 Apr; 40(4):620-625. PubMed ID: 30872420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.